Methyl salicylate / Sweet Birch oil / TumCI Cancer Research Results

MeSal, Methyl salicylate / Sweet Birch oil: Click to Expand ⟱
Features:

Methyl salicylate / Sweet Birch oil — Methyl salicylate is a small lipophilic salicylate ester and the dominant constituent of sweet birch oil and wintergreen oil. It is best classified as a natural-product-derived topical counterirritant / salicylate prodrug rather than a practical systemic anticancer agent. Natural sources include Betula lenta sweet birch and Gaultheria procumbens wintergreen, but commercial methyl salicylate is also commonly synthetic. Its cancer relevance is mainly mechanistic and indirect through salicylate biology, with major translation limits from toxicity, dermal absorption variability, and the high millimolar concentrations used in many cell studies.

Primary mechanisms (ranked):

  1. Hydrolysis to salicylate / salicylic acid, linking methyl salicylate to salicylate pharmacology rather than a distinct validated anticancer modality.
  2. COX and prostaglandin-axis suppression, reducing inflammatory signaling that can support tumor promotion and pain/inflammation pathways.
  3. NF-κB pathway inhibition, with potential suppression of survival, inflammatory, invasion, and therapy-resistance signaling in cancer contexts.
  4. AMPK activation with downstream c-MYC suppression and NRF2/ARE/miR-34a/b/c activation, reported for salicylate in colorectal cancer models.
  5. p38 MAPK-linked apoptosis and cell-cycle effects, mostly from sodium salicylate studies at pharmacologic-to-high in-vitro concentrations.
  6. Secondary mitochondrial stress / oxidative phosphorylation disruption at toxic or high concentrations, more relevant to safety than selective anticancer translation.

Bioavailability / PK relevance: Methyl salicylate is lipophilic and can penetrate skin; dermal absorption and systemic salicylate exposure are strongly formulation-, area-, dose-, heat-, and occlusion-dependent. It is rapidly hydrolyzed to salicylate, so systemic effects and toxicity resemble salicylate exposure. Oral or concentrated essential-oil exposure is a major toxicity concern and should not be treated as a supplement-like route.

In-vitro vs systemic exposure relevance: Many anticancer mechanistic studies use sodium salicylate or salicylate at millimolar concentrations, which generally exceed realistic or safe exposure targets for methyl salicylate oil. Topical use can create local tissue exposure and systemic salicylate exposure, but this is not a controlled anticancer delivery strategy. Mechanistically relevant but clinically constrained.

Clinical evidence status: Cancer evidence is preclinical / indirect, mostly extrapolated from salicylate and aspirin biology rather than methyl salicylate as an anticancer intervention. Human evidence supports topical analgesic / counterirritant use, not cancer treatment. Regulatory deployment is OTC topical analgesic/counterirritant in some jurisdictions and cosmetic/fragrance ingredient under concentration limits, with important salicylate toxicity, skin burn/irritation, sensitization, renal disease, anticoagulant, and pediatric safety constraints.

Methyl Salicylate Mechanistic Ranking

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Salicylate prodrug conversion ↔ methyl salicylate-specific targeting; ↑ salicylate exposure after hydrolysis ↑ systemic salicylate burden after dermal or oral exposure R Functional conversion to salicylate biology Most mechanistic cancer claims should be attributed to salicylate / salicylic acid rather than sweet birch oil as a complex essential oil.
2 COX prostaglandin inflammatory signaling ↓ prostaglandin-linked inflammatory support (context-dependent) ↓ inflammatory pain signaling; potential platelet / renal / gastric salicylate constraints if systemic R-G Anti-inflammatory counterirritant / salicylate effect Relevant to tumor-promoting inflammation but not a selective anticancer mechanism.
3 NF-κB survival and inflammatory signaling ↓ NF-κB activation; ↑ TNF-linked apoptosis in some cancer models ↓ inflammatory gene expression; possible impaired protective inflammatory responses R-G Reduced survival and inflammatory transcription Evidence is strongest for salicylate / aspirin class biology, not methyl salicylate oil itself.
4 AMPK c-MYC NRF2 miR-34 cascade ↑ AMPK; ↓ c-MYC; ↑ NRF2/ARE; ↑ miR-34a/b/c; ↓ migration / invasion in colorectal cancer models ↑ AMPK metabolic signaling (context-dependent) G Metabolic and tumor-suppressive microRNA modulation Mechanistically interesting for colorectal cancer, but based on salicylate concentrations that may not be safely achievable from methyl salicylate oil.
5 p38 MAPK apoptosis ↑ p38 MAPK; ↑ apoptosis (high concentration only) ↑ stress-response apoptosis risk at toxic exposure R-G Stress-activated apoptosis Useful as a mechanistic flag, but selectivity is uncertain and concentration dependence is a major limitation.
6 Mitochondrial stress and oxidative phosphorylation disruption ↑ metabolic stress (toxic concentration only) ↑ systemic toxicity risk; acid-base disturbance risk with overdose R-G Toxic salicylate pharmacology This is mainly a safety constraint rather than a therapeutic anticancer mechanism.
7 Clinical Translation Constraint ↔ no validated anticancer exposure strategy ↑ dermal absorption variability; ↑ toxicity risk with ingestion, damaged skin, large-area use, heat, occlusion, renal disease, anticoagulants, or aspirin sensitivity R-G Translation limited by toxicity and exposure control Best database placement is “mechanistic / preclinical salicylate-related,” not an actionable cancer therapy listing.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr
TumCI, Tumor Cell invasion: Click to Expand ⟱
Source:
Type:
Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.
Scientific Papers found: Click to Expand⟱
6538- MeSal,  ASA,    Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis
- in-vitro, CRC, NA
chemoPv↑, AMPK↑, NRF2↑, miR-34a↑, cMyc↓, tumCV↓, Apoptosis↑, TumCI↓, TumCMig↓, MET↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NRF2↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

miR-34a↑, 1,  

Migration ⓘ

MET↑, 1,   TumCI↓, 1,   TumCMig↓, 1,  

Functional Outcomes ⓘ

chemoPv↑, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:412  Target#:324  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page